Neutralizing antibodies and control of HIV: Moves and countermoves

Current HIV/AIDS Reports

Volumn 9, Issue 1, 2012, Pages 64-72

  Hessell, Ann J ^a   Haigwood, Nancy L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Envelope; Monoclonal antibodies; Neutralizing antibodies; Vaccines

Indexed keywords

ENVELOPE PROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ANTIBODY COMBINING SITE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE EVASION; INFECTION CONTROL; MACACA; MEMBRANE PROXIMAL EXTERNAL REGION; NONHUMAN; PROTEIN STRUCTURE; REVIEW; SUPERINFECTION; VIRUS IMMUNITY; ANIMAL; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION;

EID: 84858861298     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-011-0105-5     Document Type: Review

References (91)

1. Hicar MD, Chen X, Briney B, Hammonds J, Wang JJ, et al. Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV. J Acquir Immune Defic Syndr. 2010;54:223-35.
2. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008;105:7552-7. (Pubitemid 351830056)
3. Keele BF. Identifying and characterizing recently transmitted viruses. Curr Opin HIV AIDS. 2010;5:327-34.
4. Mahalanabis M, Jayaraman P, Miura T, Pereyra F, Chester EM, et al. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J Virol. 2009;83:662-72.
5. Medina-Ramirez M, Sanchez-Merino V, Sanchez-Palomino S, Merino-Mansilla A, Ferreira CB, et al. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. J Virol. 2011;85:5804-13.
6. Doria-Rose NA, Klein R, Daniels M, O'Dell S, Nason M, et al. Breadth of HIV-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol. 2009;84:1631-6.
7. Piantadosi A, Panteleeff D, Blish CA, Baeten JM, Jaoko W, et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol. 2009;83:10269-74.
8. Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis. 2010;201:1045-53.
9. Doria-Rose NA. HIV neutralizing antibodies: clinical correlates and implications for vaccines. J Infect Dis. 2010;201:981-3.
10. Huang KH, Bonsall D, Katzourakis A, Thomson EC, Fidler SJ, et al. B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nat Commun. 2010;1:102.
11. Samleerat T, Thenin S, Jourdain G, Ngo-Giang-Huong N, Moreau A, et al. Maternal neutralizing antibodies against a CRF01-AE primary isolate are associated with a low rate of intrapartum HIV-1 transmission. Virology. 2009;387:388-94.
12. Lynch JB, Nduati R, Blish CA, Richardson BA, Mabuka JM, et al. The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection. J Virol. 2011;85:5252-61.
13. Russell ES, Kwiek JJ, Keys J, Barton K, Mwapasa V, et al. The genetic bottleneck in vertical transmission of subtype C HIV-1 Is not driven by selection of especially neutralization-resistant virus from the maternal viral population. J Virol. 2011;85:8253-62.
14. Blish CA, Blay WM, Haigwood NL, Overbaugh J. Transmission of HIV-1 in the face of neutralizing antibodies. Curr HIV Res. 2007;5:578-87. (Pubitemid 351210992)
15. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, et al. Analysis of the neutralization specificities in polyclonal sera derived from human immunodeficiency virus type-1 infected individuals. J Virol. 2009;83:1045-59.
16. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009;458:636-40.
17. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 2010;467:591-5.
18. Sather DN, Stamatatos L. Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine. 2010;28 (Suppl 2):B8-12.
19. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 2011;7:e1001251.
20. Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, et al. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 2009;5: e1000598.
21. Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, et al. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol. 2011;85:3128-41.
22. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, et al. The neutralization breadth of HIV-1 develops incrementally over 4 years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol. 2011;85:4828-40.
23. Gray ES, Moody MA, Wibmer CK, Chen X, Marshall D, et al. Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. J Virol. 2011;85:7719-29.
24. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, et al. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 2009;5: e1000594.
25. Gnanakaran S, Daniels MG, Bhattacharya T, Lapedes AS, Sethi A, et al. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol. 2010;6:e1000955.
26. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 2004;5:233-6. (Pubitemid 38332116)
27. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol. 2004;78:13232-52. (Pubitemid 39507829)
28. Nishimura Y, Igarashi T, Haigwood N, Sadjadpour R, Plishka RJ, et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol. 2002;76:2123-30. (Pubitemid 34150679)
29. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Landucci G, et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10, directed against the human immunodeficieny virus type 1 (HIV-1) gp41 membrane proximal external region (MPER), protect against SHIVBa-L mucosal challenge. J Virol. 2009;In Press.
30. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009;5:e1000433.
31. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med. 2009;15:951-4.
32. Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS. 2008;22:339-48.
33. Bogers WM, Davis D, Baak I, Kan E, Hofman S, et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology. 2008;382:217-25.
34. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007;449:101-4. (Pubitemid 47373775)
35. Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA. 2011;108:11181-6.
36. Florese RH, Demberg T, Xiao P, Kuller L, Larsen K, et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol. 2009;182:3718-27.
37. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477:466-70.
38. Chakrabarti BK, Walker LM, Guenaga JF, Ghobbeh A, Poignard P, et al. Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity. J Virol. 2011;85:8217-26.
39. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science. 2003;300:2065-71. (Pubitemid 36760127)
40. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature. 2007;445:732-7. (Pubitemid 46279718)
41. Pejchal R, Gach JS, Brunel FM, Cardoso RM, Stanfield RL, et al. A conformational switch in HIV gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J Virol. 2009;83:8451-62.
42. Julien JP, Huarte N, Maeso R, Taneva SG, Cunningham A, et al. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. J Virol. 2010;84:4136-47.
43. Chaillon A, Braibant M, Moreau T, Thenin S, Moreau A, et al. The V1V2 domain and an N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12. J Virol. 2011;85:3642-8.
44. Klein JS, Webster A, Gnanapragasam PN, Galimidi RP, Bjorkman PJ. A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity. AIDS. 2010;24:1633-40.
45. Tudor D, Bomsel M. The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcgammaRI-dependent manner. AIDS. 2011;25:751-9.
46. Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, et al. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci USA. 2010;107:13800-5.
47. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity. 2005;22:163-73. (Pubitemid 40255708)
48. Scherer EM, Leaman DP, Zwick MB, McMichael AJ, Burton DR. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci USA. 2010;107:1529-34.
49. Montero M, van Houten NE, Wang X, Scott JK. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev. 2008;72:54-84. table of contents. (Pubitemid 351398055)
50. Alam SM, Morelli M, Dennison SM, Liao HX, Zhang R, et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA. 2009;106:20234-9.
51. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326:285-9.
52. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One. 2010;5:e8805.
53. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329:856-61.
54. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 2010;329:811-7.
55. Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol. 2011.
56. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011.
57. Bunnik EM, Euler Z, Welkers MR, Boeser-Nunnink BD, Grijsen ML, et al. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat Med. 2010;16:995-7.
58. Euler Z, Bunnik EM, Burger JA, Boeser-Nunnink BD, Grijsen ML, et al. Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J Virol. 2011;85:7236-45.
59. Woo J, Robertson DL, Lovell SC. Constraints on HIV-1 diversity from protein structure. J Virol. 2010;84:12995-3003.
60. Rusert P, Krarup A, Magnus C, Brandenberg OF, Weber J, et al. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J Exp Med. 2011;208:1419-33.
61. Bontjer I, Melchers M, Eggink D, David K, Moore JP, et al. Stabilized HIV-1 envelope glycoprotein trimers lacking the V1 V2 domain, obtained by virus evolution. J Biol Chem. 2010;285:36456-70.
62. Curlin ME, Zioni R, Hawes SE, Liu Y, Deng W, et al. HIV-1 envelope subregion length variation during disease progression. PLoS Pathog. 2010;6:e1001228.
63. Swetnam J, Shmelkov E, Zolla-Pazner S, Cardozo T. Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes. PLoS One. 2010;5:e15994.
64. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209-20.
65. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol. 2010;28:413-44.
66. Hoxie JA. Toward an antibody-based HIV-1 vaccine. Annu Rev Med. 2010;61:135-52.
67. Blish CA, Sather DN, Sellhorn G, Stamatatos L, Sun Y, et al. Comparative immunogenicity of subtype a human immunodeficiency virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes. J Virol. 2010;84:2573-84.
68. Malherbe DC, Doria-Rose NA, Misher L, Beckett T, Puryear WB, et al. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J Virol. 2011;85:5262-74.
69. Lu S, Grimes Serrano JM, Wang S. Polyvalent AIDS vaccines. Curr HIV Res. 2010;8:622-9.
70. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine. 2008;26:3947-57.
71. Vaine M, Duenas-Decamp M, Peters P, Liu Q, Arthos J, et al. Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates. J Virol. 2011;85:4927-36.
72. Basavapathruni A, Yeh WW, Coffey RT, Whitney JB, Hraber PT, et al. Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys. J Virol. 2010;84:953-63.
73. Lakhashe SK, Velu V, Sciaranghella G, Siddappa NB, Dipasquale JM, et al. Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine. 2011;29:5611-22.
74. Du SX, Xu L, Zhang W, Tang S, Boenig RI, et al. A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein. PLoS One. 2011;6:e20927.
75. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity. 2011;34:269-80.
76. Correia BE, Ban YE, Holmes MA, Xu H, Ellingson K, et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure. 2010;18:1116-26.
77. Ye L, Wen Z, Dong K, Wang X, Bu Z, et al. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines. PLoS One. 2011;6:e14813.
78. Bianchi E, Joyce JG, Miller MD, Finnefrock AC, Liang X, et al. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci USA. 2010;107:10655-60.
79. Wang J, Tong P, Lu L, Zhou L, Xu L, et al. HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies. PLoS One. 2011;6:e18233.
80. Vassilieva EV, Wang BZ, Vzorov AN, Wang L, Wang YC, et al. Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant. MBio. 2011;2: e00310-28.
81. Watkins JD, Siddappa NB, Lakhashe SK, Humbert M, Sholukh A, et al. An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS One. 2011;6:e18207.
82. Zolla-Pazner S, Kong XP, Jiang X, Cardozo T, Nadas A, et al. Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J Virol. 2011;85:9887-98.
83. Xiao P, Zhao J, Patterson LJ, Brocca-Cofano E, Venzon D, et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol. 2010;84:7161-73.
84. Stone M, Keele BF, Ma ZM, Bailes E, Dutra J, et al. A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIV-mac251. J Virol. 2010;84:7083-95.
85. Varela M, Landskron L, Lai RP, McKinley TJ, Bogers WM, et al. Molecular evolution analysis of the human immunodeficiency virus type 1 envelope in SHIV-infected macaques: implications for challenge dose selection. J Virol. 2011.
86. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature. 2010;464:217-23.
87. Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med. 2010;16:1117-9.
88. Michaud HA, Gomard T, Gros L, Thiolon K, Nasser R, et al. A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog. 2010;6:e1000948.
89. Nasser R, Pelegrin M, Michaud HA, Plays M, Piechaczyk M, et al. Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody. JVirol. 2010;84:10169-81.
90. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity. 2010;33:542-54.
91. Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization inhuman volunteers. J Infect Dis. 2011;203:1165-73.